in IND-enabling studies that targets SOD1 for the treatment of an
inherited, aggressive form of ALS, which is also known as Lou Gehrig's
disease. IND-enabling preclinical studies are being funded by the ALS
Association and the Muscular Dystrophy Association.
* Isis initiated a program to discover and develop antisense drugs to
treat Huntington's Disease in collaboration with CHDI, which is
providing Isis with nearly $10 million in funding for the program.
* Antisense Therapeutics Ltd. (ATL) licensed ATL1102 to Teva
Pharmaceutical Industries. ATL1102 is an antisense drug discovered by
Isis and licensed to ATL and is currently in Phase 2 studies for the
treatment of multiple sclerosis.
* iCo initiated Phase 1 studies of iCo-007, an antisense drug discovered
by Isis for the treatment of various eye diseases. Isis received a
$1.25 million milestone payment in equity for the initiation of this
Isis has added three major new pharmaceutical partners for drugs in its
cardiovascular and metabolic franchises, underscoring the confidence of the
industry in the promise of antisense drugs for treatment of chronic
conditions such as these:
* Isis licensed mipomersen to Genzyme as part of a strategic alliance
that includes a $150 million equity investment, an upfront licensing
fee of $175 million, over $1.5 billion in milestone payments, and a
share of profits on mipomersen and follow-on drug(s) ranging from
30-50% of all commercial sales. As part of the alliance, Genzyme
became a preferred development partner for Isis for programs in CNS
and certain rare diseases.
* Isis licensed two type 2 diabetes drugs that target GCGR and GCCR to
Johnson & Johnson's OMI for a $45
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved